Digital To fight rare diseases, win the data battle first Innovation is the key to evolution. In the pharmaceutical space, brilliant advancements have occurred with drugs with large population pools.
Market Access Evaluate’s Orphan Drug Report shows rapid acceleration in th... Paul Verdin, VP of consulting and analytics, and Andreas Hadjivasiliou, managing analyst at Evaluate, tell us about the company’s Orphan Drug Report 2022, which highlights activities within
Market Access Orphan drugs' financial success raises questions R&D into orphan drugs is growing alongside the number of approved treatments, providing treatments for rare diseases that previously did not have any.
R&D Drug development and working with specialised Rare Disease n... There are currently an estimated 300 million people living with one or more Rare Diseases across the world.
Webinars Sponsored The power of R&D collaborations to improve outcomes in rare ... Far more common than initially thought, rare disease treatments remain far too scarce.
Views & Analysis How does HTA for orphan drugs differ across Europe? New research looks at the factors that speed up and slow down HTA appraisals for rare disease medicines across Europe.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.